Brain natriuretic peptide and troponin I in acute myocardial infarction
DOI:
https://doi.org/10.5457/ams.v48i1-2.444Keywords:
myocardial infarction, brain natriuretic peptide, cardiac insufficiencyAbstract
Myocardial infarction, in the diagnostic and therapeutic aspects, is of one of the great social and medical problems. Clinical diagnosis requires the presence of clinical symptoms in combination with indirect indicators of cardiac necrosis, such as biochemical markers- enzymes, electrocardiographic (ECG) and echocardiography findings. Assessment of heart failure by determining markers of myocardial damage is very significant challenge in the process of clinical assessment of patients with myocardial infarction, for further diagnosis, treatment and prognosis. Heart failure occurs in all patients with myocardial infarction, to a lesser or greater extent. Bearing in mind that, a myocardial infarction involving the anterior wall of the heart has worse prognosis, the subject of interest of this study is whether the markers of myocardial damage will be higher in patients with this localization of myocardial infarction. It was interested too, in whether it is possible to find elevated markers of myocardial damage- failure indicators, brain natriuretic peptide, in corelation with clinical signs of cardiac insuficiency.
Downloads
Published
Issue
Section
License
Copyright transfer
The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.
